TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21148030

Group type: EXPERIMENTAL
Intervention: cinacalcet plus low‐dose vitamin D sterols (30‐180 mg/day and ≤ 2 μg paricalcitol equivalent/dialysis)
Number of subjects: 360

Group type: COMPARATOR
Intervention: flexible vitamin D therapy
Number of subjects: 360
Study: 19527191

Group type: EXPERIMENTAL
Intervention: Selegiline transdermal system (6 mg/24 h)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selegiline transdermal system (12 mg/24 h)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selegiline transdermal system (6 mg/24 h and 12 mg/24 h)
Number of subjects: 0
Study: 17242247

Group type: EXPERIMENTAL
Intervention: New calcifications classified as BI-RADS category 2 (n = 40/68; 59%) and category 3 (n = 19/68; 28%)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: New calcifications classified as BI-RADS category 4 or 5 (n = 9/68; 13%)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Median rate of development of benign calcifications
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Median rate of development of malignant calcifications
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Location of new calcifications
Number of subjects: 402
Study: 15497546

Group type: EXPERIMENTAL
Intervention: Series 10,000 machine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Diplomax machine
Number of subjects: 100
Study: 12225701

Group type: EXPERIMENTAL
Intervention: Low dose of ethanol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Stress task
Number of subjects: 40
Study: 9447863

Group type: EXPERIMENTAL
Intervention: Physostigmine (0.04 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Meperidine (0.5 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Clonidine (1.5 microg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 60
Study: 8523623

Group type: EXPERIMENTAL
Intervention: Oxandrolone (OX) plus a high caloric food supplement
Number of subjects: 271

Group type: COMPARATOR
Intervention: Matching placebo and a low calorie supplement
Number of subjects: 271
Study: 2191938

Group type: EXPERIMENTAL
Intervention: Nimodipine (10-20 mg t.i.d., according to body weight)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 375121

Group type: EXPERIMENTAL
Intervention: 2 g L-dopa + 200 mg carbodopa per day orally for 30 days
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 2 g L-dopa + 200 mg carbodopa + 300 mg imipramine orally for 30 days
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 1 mg apomorphine s.c. for 15 days
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 1 mg apomorphine s.c. + 2 g L-dopa + 200 mg carbodopa per os daily for 15 days
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo for 30 days
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo for 15 days
Number of subjects: 6
Study: 31831202

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study: 31351492

Group type: EXPERIMENTAL
Intervention: Modified minimally invasive non-surgical therapy (MINST)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Modified minimally invasive surgical therapy (M-MIST)
Number of subjects: 66
Study: 29850491

Group type: EXPERIMENTAL
Intervention: Glutamine Dipeptide (GDP) supplementation (20 g/day for 7 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Maltodextrin (control)
Number of subjects: 10
Study: 29771062

Group type: EXPERIMENTAL
Intervention: Nasal irrigation with saline
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Budesonide nasal spray
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Nasal irrigation with saline and budesonide
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Nasal spray with 2.3% hypertonic saline
Number of subjects: 75
Study: 24615948

Group type: EXPERIMENTAL
Intervention: Prolift Total
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sacrospinous fixation (SSF)
Number of subjects: 70
Study: 21844879

Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Liraglutide 2.4/3.0 mg (pooled group)
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Liraglutide 2.4/3.0 mg (completers)
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Liraglutide 2.4/3.0 mg
Number of subjects: 564

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 564

Group type: COMPARATOR
Intervention: Orlistat 120 mg × 3
Number of subjects: 564
Study: 19106739

Group type: EXPERIMENTAL
Intervention: theory‐based smoking reduction intervention that combined telephone counseling and tailored newsletters
Number of subjects: 320

Group type: COMPARATOR
Intervention: enhanced usual care
Number of subjects: 320
Study: 17484348

Group type: EXPERIMENTAL
Intervention: 80‐mg atorvastatin for 4 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 15115251

Group type: EXPERIMENTAL
Intervention: Cortisone-acetate (12.5 mg at 16.00 h and 25 mg at 07.00 h)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Healthy controls (N=8)
Number of subjects: 11
Study: 11135718

Group type: EXPERIMENTAL
Intervention: Low-flow sevoflurane plus probenecid (LSP)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Low-flow sevoflurane (LS)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: High-flow sevoflurane plus probenecid (HSP)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: High-flow sevoflurane (HS)
Number of subjects: 64
Study: 9576423

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7881705

Group type: EXPERIMENTAL
Intervention: Bevantolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study: 2908300

Group type: EXPERIMENTAL
Intervention: Carvedilol 25mg twice daily
Number of subjects: 49

Group type: COMPARATOR
Intervention: Metoprolol 50mg twice daily
Number of subjects: 49
Study: 31821014

Group type: EXPERIMENTAL
Intervention: Exercise-based intervention
Number of subjects: 112
Study: 29553901

Group type: EXPERIMENTAL
Intervention: Fresh-frozen canine cadavers (FFCCs)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Canine simulator
Number of subjects: 48
Study: 27117690

Group type: EXPERIMENTAL
Intervention: Transoral laser microsurgery (TLM)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Vertical hemilaryngectomy
Number of subjects: 56
Study: 25280934

Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 μg
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 24360050

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Dex) 0.3 µg/kg intravenously for initial bolus (duration 15 min) and then 0.3 µg·kg(‐1)·h(‐1) continuous infusion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Dex) 0.5 µg/kg intravenously (duration 15 min) for initial load and then 0.3 µg·kg(‐1)·h(‐1) continuous infusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: No sedative anesthetic
Number of subjects: 60
Study: 20728808

Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids rescue courses (betamethasone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multiple courses of antenatal corticosteroids
Number of subjects: 0
Study: 18461376

Group type: EXPERIMENTAL
Intervention: Active suction device (S)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control, nonsuction device (NS)
Number of subjects: 0
Study: 17131979

Group type: EXPERIMENTAL
Intervention: Spirituality group (8-week audiotaped spirituality home-study program)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation group (attendance at facilitated classes for 8 weeks)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Wait-list control group (no intervention for 12 weeks)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Spirituality group
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation group
Number of subjects: 165

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 165
Study: 14656280

Group type: EXPERIMENTAL
Intervention: Intraperitoneal cisplatin (90 mg/m2 every 3 weeks)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Observation (no further treatment)
Number of subjects: 153
Study: 10962520

Group type: EXPERIMENTAL
Intervention: Valyl-Tyrosine (VY) 3 mg in a 100-ml drink administered twice a day for 4 weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo drink (100-ml)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Valyl-Tyrosine (VY)
Number of subjects: 29
Study: 8783393

Group type: EXPERIMENTAL
Intervention: 0.125 mg triazolam (TRZ)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7880476

Group type: EXPERIMENTAL
Intervention: Gluma 3 Primer
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Gluma 2000 Conditioner
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control
Number of subjects: 34
Study: 3510286

Group type: EXPERIMENTAL
Intervention: Dexamethasone (50 mg IV bolus on admission, then 100 mg on Days 1, 2, and 3, 50 mg on Day 4, and 25 mg on Day 5 on continuous IV infusion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30352997

Group type: EXPERIMENTAL
Intervention: Music intervention (n = 26)
Number of subjects: 51
Study: 27066739

Group type: EXPERIMENTAL
Intervention: ICS withdrawal group
Number of subjects: 2296

Group type: COMPARATOR
Intervention: ICS continuation group
Number of subjects: 2296
Study: 25569441

Group type: EXPERIMENTAL
Intervention: Polygenic risk quartiles 1 to 4 (1: 9%, 2: 18%, 3: 25%, 4: 48%)
Number of subjects: 17012

Group type: EXPERIMENTAL
Intervention: Polygenic risk quartiles
Number of subjects: 17012
Study: 23183261

Group type: EXPERIMENTAL
Intervention: TENS at 2 pps
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: TENS at 30 pps
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: TENS at 80 pps
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: TENS at lower back
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: TENS at tibia and forearm
Number of subjects: 30
Study: 22041002

Group type: EXPERIMENTAL
Intervention: Child him/herself in front of the mirror
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Another person with the child in the mirror
Number of subjects: 141

Group type: COMPARATOR
Intervention: Giant TBM
Number of subjects: 141

Group type: COMPARATOR
Intervention: Animal TBM puppet
Number of subjects: 141
Study: 18257133

Group type: EXPERIMENTAL
Intervention: Test formulation of risperidone tablets
Number of subjects: 18

Group type: COMPARATOR
Intervention: Reference formulation of risperidone tablets
Number of subjects: 18
Study: 16204301

Group type: EXPERIMENTAL
Intervention: CsA microemulsion (CsA‐ME)
Number of subjects: 98
Study: 12657097

Group type: EXPERIMENTAL
Intervention: Flutamide
Number of subjects: 37

Group type: COMPARATOR
Intervention: LHRH agonist
Number of subjects: 37
Study: 10723579

Group type: EXPERIMENTAL
Intervention: lenograstim at 8 micrograms/kg/day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: lenograstim at 11 micrograms/kg/day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: lenograstim at 15 micrograms/kg/day
Number of subjects: 36
Study: 8991589

Group type: COMPARATOR
Intervention: Estrogen therapy alone
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Estrogen therapy with nomegestrol acetate
Number of subjects: 351
Study: 1541084

Group type: EXPERIMENTAL
Intervention: Computer-assisted femoral arteriography
Number of subjects: 114

Group type: COMPARATOR
Intervention: Physiological tests
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (ankle-arm ratio)
Number of subjects: 114
Study: 3886943

Group type: EXPERIMENTAL
Intervention: Comprehensive hospice care
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional medical care
Number of subjects: 100
Study: 30859380

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI) with manual thrombus aspiration
Number of subjects: 144

Group type: COMPARATOR
Intervention: Primary percutaneous coronary intervention (PCI) without manual thrombus aspiration (control)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Both groups (PCI with and without thrombus aspiration)
Number of subjects: 144
Study: 29534736

Group type: COMPARATOR
Intervention: Sipuleucel-T alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sipuleucel-T followed by pTVG-HP DNA vaccine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study: 26882043

Group type: EXPERIMENTAL
Intervention: VTP-27999 (75-600 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Aliskiren (300 mg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: VTP-27999 (150 mg)
Number of subjects: 22
Study: 25141850

Group type: EXPERIMENTAL
Intervention: iStoppFalls system exercise program (16-week duration, 180 minutes/week)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: iStoppFalls system exercise program
Number of subjects: 160
Study: 22313154

Group type: EXPERIMENTAL
Intervention: saxagliptin 5 mg once daily for 24 weeks
Number of subjects: 455

Group type: COMPARATOR
Intervention: placebo once daily for 24 weeks
Number of subjects: 455
Study: 20729527

Group type: EXPERIMENTAL
Intervention: Alcohol cues
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Polydrug cues
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Marijuana cues
Number of subjects: 10
Study: 17563091

Group type: EXPERIMENTAL
Intervention: Current use of long-acting benzodiazepines
Number of subjects: 18490

Group type: EXPERIMENTAL
Intervention: Current use of long-acting benzodiazepines (restricted to subjects with four or less prescriptions filled in the previous year)
Number of subjects: 18490

Group type: COMPARATOR
Intervention: Case-crossover approach (all cases)
Number of subjects: 18490
Study: 16154346

Group type: EXPERIMENTAL
Intervention: Infusion of ephedrine 30 mg in 1 L of 0.9% saline after spinal block, titrated to maternal systolic pressure.
Number of subjects: 60

Group type: COMPARATOR
Intervention: 1 L 0.9% saline before spinal block (control group).
Number of subjects: 60
Study: 12012141

Group type: COMPARATOR
Intervention: Topotecan alone (1.5 mg/m² for 5 days)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Topotecan with amifostine (300 mg/m² prior to topotecan)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Topotecan alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Topotecan with amifostine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Topotecan only
Number of subjects: 10
Study: 10604482

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 37

Group type: COMPARATOR
Intervention: Normotensive controls
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Perindopril and Losartan
Number of subjects: 37
Study: 7782137

Group type: EXPERIMENTAL
Intervention: 250 ml 20% mannitol infusion and 10.0 g ascorbic acid infusion
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard fibrinolytic therapy (control group)
Number of subjects: 42
Study: 1486827

Group type: EXPERIMENTAL
Intervention: 7.5 mg Zopiclone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6371412

Group type: EXPERIMENTAL
Intervention: Tonsillectomy using electrocautery for dissection and hemostasis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tonsillectomy performed by scissor dissection with suture hemostasis
Number of subjects: 0
Study: 30770192

Group type: COMPARATOR
Intervention: Condition 1 (sitting for 7h interrupted by 3min light-intensity walking breaks every 60min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Condition 2 (sitting for 7h interrupted by 3min light-intensity walking breaks every 30min)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Condition 3 (sitting for 7h interrupted by 3min light-intensity walking breaks every 15min)
Number of subjects: 12
Study: 30410129

Group type: EXPERIMENTAL
Intervention: Umbilical cord milking
Number of subjects: 75

Group type: COMPARATOR
Intervention: Early cord clamping
Number of subjects: 75
Study: 27245918

Group type: EXPERIMENTAL
Intervention: Vibration on the less affected limb (LA)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Vibration applied after FOG onset
Number of subjects: 16
Study: 25304446

Group type: EXPERIMENTAL
Intervention: Personality assessment and life events evaluation
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Social cognition tests
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Social cognition performance
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Brain Magnetic Resonance Imaging
Number of subjects: 252
Study: 22453200

Group type: EXPERIMENTAL
Intervention: Progesterone (300 mg daily at bedtime)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 20525836

Group type: EXPERIMENTAL
Intervention: RANKL:OPG ratio and CTX‐I or CTX‐II
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Treatment at 3 months
Number of subjects: 155
Study: 18027874

Group type: EXPERIMENTAL
Intervention: Terlipressin (2 mg injection)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 15608522

Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 16
Study: 12373046

Group type: EXPERIMENTAL
Intervention: Patients with ST-T-changes
Number of subjects: 85

Group type: COMPARATOR
Intervention: Patients without ECG alterations
Number of subjects: 85
Study: 10418916

Group type: EXPERIMENTAL
Intervention: Plasma-derived hepatitis B vaccine
Number of subjects: 649

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 649
Study: 8526975

Group type: EXPERIMENTAL
Intervention: Ketamine 0.3 mg/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Ketamine (various doses)
Number of subjects: 6
Study: 2344010

Group type: EXPERIMENTAL
Intervention: Bromocriptine treatment for four months
Number of subjects: 10
Study: 7047536

Group type: EXPERIMENTAL
Intervention: Radical resection of the lesion and the insertion of autologous bone grafts (Rad. series)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Debridement of the spinal focus without bone grafting (Deb. series)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Rad. series
Number of subjects: 119

Group type: COMPARATOR
Intervention: Deb. series
Number of subjects: 119
Study: 31114950

Group type: EXPERIMENTAL
Intervention: Optical guidance
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mechanical guidance
Number of subjects: 60

Group type: COMPARATOR
Intervention: Blind insertion
Number of subjects: 60
Study: 30849952

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard Therapy (ST)
Number of subjects: 72
Study: 30033111

Group type: COMPARATOR
Intervention: Limbal relaxing incisions (LRIs)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Femtosecond laser arcuate keratotomy
Number of subjects: 104
Study: 26984911

Group type: EXPERIMENTAL
Intervention: OP-1 combined with local bone
Number of subjects: 119

Group type: COMPARATOR
Intervention: Iliac crest autograft combined with local bone
Number of subjects: 119
Study: 24009162

Group type: EXPERIMENTAL
Intervention: Internet-delivered behavioral intervention
Number of subjects: 82
Study: 21525141

Group type: EXPERIMENTAL
Intervention: Dioctahedral smectite (DS) 1.5 g thrice daily for 5 days
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Dioctahedral smectite (DS)
Number of subjects: 117
Study: 19783713

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil 1000 mg with pantoprazole 40 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium with pantoprazole 40 mg twice daily
Number of subjects: 0
Study: 17845320

Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg b.i.d. for 48 h
Number of subjects: 104

Group type: COMPARATOR
Intervention: Intravenous magnesium sulfate for maximum of 48 h
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Celecoxib and magnesium sulfate
Number of subjects: 104
Study: 15237025

Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional in vitro fertilization (IVF)
Number of subjects: 0
Study: 12296413

Group type: EXPERIMENTAL
Intervention: Test product (Unison Laboratories, Thailand)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Reference product (Glaxo Wellcome, USA)
Number of subjects: 14
Study: 9791049

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (0, 20 and 40 p.p.m.)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nebulized prostaglandin I2 (10 microgram/ml)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Bicycle ergometry (positive control)
Number of subjects: 8
Study: 7988077

Group type: EXPERIMENTAL
Intervention: Lp(a) lipoprotein levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HLA class II genotypes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relative risk for CAD
Number of subjects: 0
Study: 2563839

Group type: EXPERIMENTAL
Intervention: Echocardiography
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Aortography
Number of subjects: 164
Study: 31340760

Group type: EXPERIMENTAL
Intervention: Lasmiditan 50 mg (SPARTAN only)
Number of subjects: 3981

Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg
Number of subjects: 3981

Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg
Number of subjects: 3981

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3981

Group type: EXPERIMENTAL
Intervention: Lasmiditan (all doses)
Number of subjects: 3981

Group type: COMPARATOR
Intervention: Lasmiditan and Placebo
Number of subjects: 3981
Study: 27997285

Group type: EXPERIMENTAL
Intervention: Gain-framed messages
Number of subjects: 132

Group type: COMPARATOR
Intervention: Loss-framed messages
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Short-term consequences
Number of subjects: 132

Group type: COMPARATOR
Intervention: Long-term consequences
Number of subjects: 132
Study: 25569654

Group type: EXPERIMENTAL
Intervention: Fentanyl combined with etomidate (fentanyl 1 to 2 μg/kg, etomidate 0.1 to 0.3 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lidocaine only (control group)
Number of subjects: 0